Genomics Bioscience & Technology Co

Genomics Bioscience & Technology Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Genomics Bioscience & Technology Co (4195.TWO) as of Oct 9, 2026 is 435.36 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 136.80 % — a change of 218.25% (higher).

FCF Conversion

435.36 %

YoY

218.25%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Genomics Bioscience & Technology Co is 2025 435.36 % . FCF Conversion Rate (FCF/EBITDA) of Genomics Bioscience & Technology Co was 2024 136.80 % . It decreases by 218.25% higher compared to the previous year.

The Genomics Bioscience & Technology Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-64.10 TWD
Jan 1, 2019
315.61 TWD
Jan 1, 2020
-10,544.43 TWD
Jan 1, 2021
-654.16 TWD
Jan 1, 2022
-161.13 TWD
Jan 1, 2023
147.20 TWD
Jan 1, 2024
136.80 TWD
Jan 1, 2025
435.36 TWD
The Genomics Bioscience & Technology Co FCF Conversion history
YEARFCF ConversionYoY
435.36 %+218.25%
136.80 %-7.07%
147.20 %-191.36%
-161.13 %-75.37%
-654.16 %-93.80%
-10,544.43 %-3,440.96%
315.61 %-592.35%
-64.10 %-126.49%
241.97 %+10.08%
219.81 %-171.67%
-306.68 %-168.01%
450.96 %—
Access this data via the Eulerpool API
Get Free API Key

Genomics Bioscience & Technology Co Stock analysis

What does Genomics Bioscience & Technology Co do? Genomics Bioscience & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomics Bioscience & Technology Co stock

FCF Conversion Rate (FCF/EBITDA) of Genomics Bioscience & Technology Co is 435.36 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Genomics Bioscience & Technology Co changed from 136.80 % to 435.36 %, representing a 218.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Genomics Bioscience & Technology Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Genomics Bioscience & Technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API
Get Free API Key

Cash Flow — Genomics Bioscience & Technology Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Genomics Bioscience & Technology Co